Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.
Jonathan S. Levin, PhD
Advertisement
Articles by Jonathan S. Levin, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Patient Portal Messages Outpace Office Visits
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
5